Is Vanda Pharmaceuticals a Chinese company?
Vanda is based in Washington DC and was found in 2003. Vanda (VNDA) is a NASDAQ traded company since 2006. History. Vanda is based in Washington DC and was found in 2003. Vanda (VNDA) is a NASDAQ traded company since 2006. Vanda is founded on the principles of the application of advanced scientific methodology in the development of therapeutics.Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.Feb 20 (Reuters) – The U. S. Food and Drug Administration has approved Vanda Pharmaceuticals’ (VNDA. O) , opens new tab drug for the treatment of two serious mental health conditions, the company said on Friday, sending its shares surging 30% in extended trading.About us. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Who are Vanda Pharmaceuticals competitors?
NVAX, ZBIO, GERN, OPK, and MNKD. Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Novavax (NVAX), Zenas BioPharma (ZBIO), Geron (GERN), OPKO Health (OPK), and MannKind (MNKD). These companies are all part of the biotechnology industry. Corporate Governance We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients. Our CEO, Mihales Polymeropoulos, MD, founded Vanda in 2003.
Is Vanda Pharmaceuticals a good company to work for?
Vanda Pharmaceuticals has an employee rating of 3. Glassdoor which indicates that most employees have a good working experience there. Dana Incorporated has an employee rating of 3. Glassdoor which indicates that most employees have a good working experience there.
What is the target price for Vanda Pharmaceuticals?
Based on short-term price targets offered by five analysts, the average price target for Vanda Pharmaceuticals comes to $15. The forecasts range from a low of $7. The average price target represents an increase of 114. According to the 8 analysts’ twelve-month price targets for Vanda Pharmaceuticals, the average price target is $14. The highest price target for VNDA is $24. VNDA is $7. The average price target represents a forecasted upside of 106.Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.